Back to Search
Start Over
Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia.
- Source :
-
Journal of diabetes science and technology [J Diabetes Sci Technol] 2024 Nov; Vol. 18 (6), pp. 1416-1423. Date of Electronic Publication: 2023 Jul 14. - Publication Year :
- 2024
-
Abstract
- Background: This study assessed changes in actigraphy-estimated sleep and glycemic outcomes after initiating automated insulin delivery (AID).<br />Methods: Ten adults with long-standing type 1 diabetes and impaired awareness of hypoglycemia (IAH) participated in an 18-month clinical trial assessing an AID intervention on hypoglycemia and counter-regulatory mechanisms. Data from eight participants (median age = 58 years) with concurrent wrist actigraph and continuous glucose monitoring (CGM) data were used in the present analyses. Actigraphs and CGM measured sleep and glycemic control at baseline (one week) and months 3, 6, 9, 12, 15, and 18 (three weeks) following AID initiation. HypoCount software integrated actigraphy with CGM data to separate wake and sleep-associated glycemic measures. Paired sample t -tests and Cohen's d effect sizes modeled changes and their magnitude in sleep, glycemic control, IAH (Clarke score), hypoglycemia severity (HYPO score), hypoglycemia exposure (CGM), and glycemic variability (lability index [LI]; CGM coefficient-of-variation [CV]) from baseline to 18 months.<br />Results: Sleep improved from baseline to 18 months (shorter sleep latency [ P < .05, d = 1.74], later sleep offset [ P < .05, d = 0.90], less wake after sleep onset [ P < .01, d = 1.43]). Later sleep onset ( d = 0.74) and sleep midpoint ( d = 0.77) showed medium effect sizes. Sleep improvements were evident from 12 to 15 months after AID initiation and were preceded by improved hypoglycemia awareness (Clarke score [ d = 1.18]), reduced hypoglycemia severity (HYPO score [ d = 2.13]), reduced sleep-associated hypoglycemia (percent time glucose was < 54 mg/dL, < 60 mg/dL,< 70 mg/dL; d = 0.66-0.81), and reduced glucose variability (LI, d = 0.86; CV, d = 0.62).<br />Conclusion: AID improved sleep initiation and maintenance. Improved awareness of hypoglycemia, reduced hypoglycemia severity, hypoglycemia exposure, and glucose variability preceded sleep improvements.This trial is registered with ClinicalTrials.gov NCT03215914 https://clinicaltrials.gov/ct2/show/NCT03215914.<br />Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Subjects :
- Humans
Middle Aged
Male
Female
Aged
Adult
Blood Glucose Self-Monitoring
Actigraphy
Awareness
Hypoglycemia blood
Hypoglycemia prevention & control
Diabetes Mellitus, Type 1 drug therapy
Diabetes Mellitus, Type 1 blood
Diabetes Mellitus, Type 1 complications
Insulin administration & dosage
Insulin adverse effects
Insulin Infusion Systems
Hypoglycemic Agents administration & dosage
Hypoglycemic Agents adverse effects
Sleep drug effects
Blood Glucose analysis
Blood Glucose drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1932-2968
- Volume :
- 18
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of diabetes science and technology
- Publication Type :
- Academic Journal
- Accession number :
- 37449426
- Full Text :
- https://doi.org/10.1177/19322968231182406